Though optimistic, speakers at the recent LSX World Congress in London, UK, recognised that recent turbulence in the wake of ...

Good morning, Boston, and happy Friday. Here are the five things you need to know in local business news to start your busy day, including Moderna's cost cuts, "misunderstood" Wayfair, the highest ...

Universities and companies that turn discoveries into medicines in Seattle have searched for “safe harbor” from the White ...

Among three Korean biotech companies slated to sell shares on the Korea Exchange this month, Immuneoncia Therapeutics Inc. is ...

The market turbulence unleashed by President Donald Trump’s tariff policies will likely evaporate the trickle of biotech IPOs that were expected in 2025, a capital markets expert has told Fierce.

After a decade of significant challenges, biotech's long-term sustainability depends on making fundamental changes to its traditional business model. A commonly held perception in the biotech ...

Jyong Biotech Ltd. (Revived IPO) (MENS) is planning to raise $22 million in an initial public offering (IPO) on Wednesday, April 16th, IPO Scoop reports. The company plans to issue 2,700,000 ...

Biotech was starting to show signs of recovery after years of investor pullback—until new tariffs and economic uncertainty ...

“We were probably one of the lucky few that was able to go out last fall and have such a strong and successful IPO,” Bicara CEO Claire Mazumdar, Ph.D., told Fierce Biotech at the end of last week.

At the beginning of the year, pharma M&A was expected to rise and the biotech IPO market appeared steady. Now, the biotech space has been roiled by several abrupt changes stemming from new Trump ...